Bladder cancer

Current Opinion in Oncology

Volumn 22, Issue 3, 2010, Pages 242-249

  Morgan, Todd M ^a   Clark, Peter E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bladder cancer; Diagnosis; Review; Treatment

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; LAPATINIB; METHOTREXATE; MITOMYCIN C; PACLITAXEL; SORAFENIB; VINBLASTINE;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER INVASION; CYSTECTOMY; CYSTOSCOPY; FLUORESCENT LIGHTING; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPHADENECTOMY; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; ROBOTICS; SENSITIVITY AND SPECIFICITY;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; NEOADJUVANT THERAPY; URINARY BLADDER NEOPLASMS;

EID: 77951463647     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283378c6b     Document Type: Review

References (96)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Denzinger S, Wieland WF, Otto W, et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2008; 101:566-569.
3. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007; 178:62-67. (Pubitemid 46908731)
4. Goh AC, Tresser NJ, Shen SS, et al. Optical coherence tomography as an adjuncttowhite light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 2008; 72:133-137.
5. Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with highresolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009; 56:914-919.
6. Sonn GA, Jones S-NE, Tarin TV, et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol 2009; 182:1299-1305.
7. Chade DC, Shariat S, Godoy G, et al. Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Men Health 2009; 6:368-382.
8. Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology 2009; 73:592-596; discussion 596-597.
9. Lotan Y, Capitanio U, Shariat SF, et al. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009; 103:1368-1374.
10. Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009; 182:52-57; discussion 58.
11. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: metaanalysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26:646-651.
12. Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical bacillus Calmette-Guerin therapy. Int J Cancer 2009; 124:2899-2904.
13. Whitson J, Berry A, Carroll P, et al. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009; 104:336-339.
14. Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27:3929-3937.
15. Wang R, Morris DS,TomlinsSA, et al. Development of a multiplex quantitative PCR signature to predict progression in nonmuscle-invasive bladder cancer. Cancer Res 2009; 69:3810-3818.
16. de Bekker-Grob EW, van der Aa MNM, Zwarthoff EC, et al. Nonmuscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int 2009; 104:41-47.
17. Zieger K, Wiuf C, Jensen KM, et al. Chromosomal imbalance in the progression of high-risk nonmuscle invasive bladder cancer. BMC Cancer 2009; 9:149.
18. Feldman AS, Banyard J, Wu C-L, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res 2009; 15:1024-1031.
19. Schiffer E, Vlahou A, Petrolekas A, et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res 2009; 15:4935-4943.
20. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178:2314-2330.
21. Hollenbeck BK, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst 2009; 101:571-580.
22. Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171:2186-2190; quiz 2435.
23. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54:303-314.
24. Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with nonmuscle-invasive bladder cancer receive early intravesical chemotherapy after transur ethral resection? The results of a prospective randomised multicentre study. Eur Urol 2009; 55:773-780.
25. Dutta SC, Smith JA, Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166:490-493.
26. Kulkarni G, Hakenberg O, Gschwend J, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010; 57:60-70.
27. Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk nonmuscle invasive bladder cancer (T1 G3). World J Urol 2009; 27:347-351.
28. Holmang S, Hedelin H, Anderstrom C, et al. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997; 157:800-803; discussion 804.
29. Masood S, SriprasadS, Palmer JH, etal. T1G3 bladder cancer: indications for early cystectomy. Int Urol Nephrol 2004; 36:41-44.
30. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-nontreated patients. Eur Urol 2005; 48:231-238; discussion 238.
31. Weizer AZ, Wasco MJ, Wang R, et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J Urol 2009; 182:59-65; discussion 65.
32. Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007; 70:758-762.
33. ChoK, Seo H, Joung J, etal. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 2009; 182:2625-2631.
34. Shariat SF, MargulisV, Lotan Y, etal. Nomograms for bladder cancer. Eur Urol 2008; 54:41-53.
35. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477.
36. Malmstrom P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for nonmuscle-invasive bladder cancer. Eur Urol 2009; 56:247-256.
37. Lamm DL, Blumenstein BA, Crissman JD, etal. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163:1124-1129.
38. Witjes AJ, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009; 27:319-324.
39. Di Stasi SM, Riedl C. Updates in intravesical electromotive drug administration of mitomycin-C for nonmuscle invasive bladder cancer. World J Urol 2009; 27:325-330.
40. Jain A, Phillips RM, Scally AJ, et al. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 2009; 73:1083-1086.
41. van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 2006; 176:1349-1353; discussion 1353.
42. Steinberg G, Bahnson R, Brosman S, etal. Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163:761-767.
43. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol 2009; 181:1040-1045.
44. Sidi AA, Ohana P, Benjamin S, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 2008; 180:2379-2383.
45. Stein JP, Lieskovsky G, Cote R, etal. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
46. Stein JP, Penson DF, Lee C, etal. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol 2009; 181:2052-2058; discussion 2058-2059.
47. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55:164-176.
48. Lowrance WT, Rumohr JA, Chang SS, et al. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol 2008; 179:1313-1318; discussion 1318.
49. Barbieri CE, Lee B, Cookson MS, etal. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 2007; 178:1418-1421; discussion 1421-11412
50. Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 2007; 178:2308-2312; discussion 2313.
51. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22:2781-2789.
52. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169:943-945.
53. Wright JL, Lin DW, Porter MP. The association between extent of lympha-denectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008; 112:2401-2408.
54. Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008; 26:121-126.
55. Bruins HM, Huang GJ, Cai J, et al. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 2009; 182:2182-2187.
56. Hellenthal NJ, Ramirez ML, Evans CP, et al. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol 2009; 181:2490-2495.
57. Guillotreau J, Game X, Mouzin M, etal. Radical cystectomy for bladder cancer: morbidity of laparoscopic versus open surgery. J Urol 2009; 181:554-559; discussion 559.
58. Murphy DG, Challacombe BJ, Elhage O, etal. Robotic-assisted laparoscopic radical cystectomy with extracorporeal urinary diversion: initial experience. Eur Urol 2008; 54:570-580.
59. Pruthi RS, Wallen EM. Robotic-assisted laparoscopic radical cystoprosta-tectomy. Eur Urol 2008; 53:310-322.
60. Wang G, Barocas D, Raman J, et al. Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 2008; 101:89-93.
61. Ng C, Kauffman E, Lee M, etal. A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 2010; 57:274-282.
62. Pruthi RS, Smith A, Wallen EM. Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 2008; 22:2469-2474.
63. Haber G-P, Crouzet S, Gill IS. Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis. Eur Urol 2008; 54:54-62.
64. Botto H, Sebe P, Molinie V, et al. Prostatic capsule-and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients. BJU Int 2004; 94:1021-1025.
65. Muto G, Bardari F, D'Urso L, et al. Seminal sparing cystectomy and ileo-capsuloplasty: long-term followup results. J Urol 2004; 172:76-80.
66. Vallancien G, Abou El Fettouh H, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002; 168:2413-2417.
67. Rozet F, Lesur G, Cathelineau X, et al. Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol 2008; 179:2170-2174; discussion 2174-2175.
68. Stein JP, Hautmann RE, Penson D, et al. Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. Urol Oncol 2009; 27:466-472.
69. Pettus J, Al-Ahmadie H, Barocas D, et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 2008; 53:370-375.
70. Revelo MP, Cookson MS, Chang SS, etal. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004; 171:646-651.
71. Hekal IA, El-Bahnasawy MS, Mosbah A, et al. Recoverability of erectile function in postradical cystectomy patients: subjective and objective evaluations. Eur Urol 2009; 55:275-283.
72. Rodel C, Grabenbauer GG, Kühn R, etal. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071.
73. Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008; 54:126-132.
74. Solsona E, Climent MA, Iborra I, et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-upof a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:911-919.
75. Herr HW. Editorial comment on: Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55:920-921.
76. Oh KS, Soto DE, Smith DC, et al. Combined-modality therapy with gemci-tabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2009; 74:511-517.
77. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055-4061.
78. Chang SS, Hassan JM, Cookson MS, et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003; 170:1085-1087.
79. Gore JL, Lai J, Setodji CM, etal. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 2009; 115:988-996.
80. Kulkarni GS, Urbach DR, Austin PC, et al. Longer wait times increase overall mortality in patients with bladder cancer. J Urol 2009; 182:1318-1324.
81. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol 2009; 55:348-358.
82. Grossman HB, Natale RB,Tangen CM, etal. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-866.
83. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) metaanalysis collaboration. Eur Urol 2005; 48:202-205.
84. Porter M, Kerrigan M, Donato B, et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2010 [Epub ahead of print].
85. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis of individual patient data Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Eur Urol 2005; 48:189-199.
86. Millikan R, Dinney C, Swanson D, etal. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005-4013.
87. Kassouf W, Agarwal PK, Grossman HB, et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2009; 73:147-152.
88. Loehrer PJ, Einhorn LH, Elson PJ, etal. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10:1066-1073.
89. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113:2471-2477.
90. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608.
91. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42:50-54.
92. Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009; 27:4062-4067.
93. Calabro F, Lorusso V, Rosati G, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 2009; 115:2652-2659.
94. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115:4090-4095.
95. Wülfing C, Machiels J-PH, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115:2881-2890.
96. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115:4110-4117.